R-ICE versus R-ESHAP for salvage therapy in aggressive B-cell non-Hodgkin lymphoma.

被引：0
|
作者：
Freyer, Craig [1 ]
George, Timothy [1 ]
Price, Samantha [1 ]
Shah, Bijal Dinesh [1 ]
Bello, Celeste M. [1 ]
Sokol, Lubomir [1 ]
Sotomayor, Eduardo M. [1 ]
Cultrera, Jennifer L. [1 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18509
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions
    Jurczak, Wojciech
    Dlugosz-Danecka, Monika
    Navarro, Fernando Rivas
    FUTURE ONCOLOGY, 2019, 15 (03) : 305 - 317
  • [22] Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy
    Uchida, Mayako
    Murata, Saeko
    Morikawa, Hanae
    Yonemitsu, Hiroko
    Ishida, Shigeru
    Suetsugu, Kimitaka
    Tsuji, Toshikazu
    Watanabe, Hiroyuki
    Kawashiri, Takehiro
    Kato, Koji
    Hosohata, Keiko
    Miyamoto, Toshihiro
    Egashira, Nobuaki
    Nakamura, Tsutomu
    Akashi, Koichi
    Ieiri, Ichiro
    ANTICANCER RESEARCH, 2022, 42 (04) : 2053 - 2060
  • [23] Antibody therapy of non-Hodgkin's B-cell lymphoma
    Paul Chinn
    Gary Braslawsky
    Christine White
    Nabil Hanna
    Cancer Immunology, Immunotherapy, 2003, 52 : 257 - 280
  • [24] Antibody therapy of non-Hodgkin's B-cell lymphoma
    Chinn, P
    Braslawsky, G
    White, C
    Hanna, N
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (05) : 257 - 280
  • [25] Phase 1 b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma.
    Zelenetz, Andrew David
    Salles, Gilles A.
    Mason, Kylie D.
    Casulo, Carla
    Le Gouill, Steven
    Sehn, Laurie Helen
    Tilly, Herve
    Cartron, Guillaume
    Chamuleau, Martine E. D.
    Goy, Andre
    Tam, Constantine
    Lugtenburg, Pieternella J.
    Elstrom, Rebecca L.
    Hsu, Wanling
    Mobasher, Mehrdad
    Morschhauser, Franck
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Hepatitis c virus infection and B-cell non-Hodgkin's lymphoma.
    Grudeva, JG
    BLOOD, 2005, 106 (11) : 247B - 247B
  • [27] Rituximab increases response to ESHAP in relapsed, refractory, and transformed aggressive B-Cell lymphoma.
    Hicks, Lisa
    Buckstein, Rena
    Mangel, Joy
    Piliotis, Eugenia
    Imrie, Kevin
    Cheung, Matthew C.
    Spaner, David E.
    Reis, Marciano D.
    Ghorab, Zeina
    Milliken, Violet
    Pennell, Nancy
    Berinstein, Neil
    BLOOD, 2006, 108 (11) : 873A - 874A
  • [28] Chemokine upregulation in response to rituximab in B-cell non-Hodgkin's lymphoma.
    Ansell, SM
    Tschumper, RC
    Witzig, TE
    Kurtin, PJ
    Jelinek, DF
    BLOOD, 1999, 94 (10) : 86A - 86A
  • [29] Clinical trials of dendritic cell vaccination for B-cell non-Hodgkin's lymphoma.
    Timmerman, JM
    Davis, TA
    Hsu, FJ
    Benike, C
    Liles, TM
    Czerwinski, D
    Taidi, B
    van Beckhoven, A
    Fazio, M
    Engleman, EG
    Levy, R
    JOURNAL OF LEUKOCYTE BIOLOGY, 1998, : 15 - 15
  • [30] Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma
    Vose, J
    Sneller, V
    ANNALS OF ONCOLOGY, 2003, 14 : 17 - 20
12345